Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Net Cash Flow (2016 - 2025)

Apyx Medical's Net Cash Flow history spans 15 years, with the latest figure at $6.7 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 86.7% year-over-year to $6.7 million; the TTM value through Dec 2025 reached $465000.0, up 103.87%, while the annual FY2025 figure was $465000.0, 103.87% up from the prior year.
  • Net Cash Flow reached $6.7 million in Q4 2025 per APYX's latest filing, up from -$4.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $21.5 million in Q4 2023 to a low of -$6.4 million in Q1 2024.
  • Average Net Cash Flow over 5 years is -$506450.0, with a median of -$3.1 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: tumbled 2882.17% in 2022, then soared 560.04% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$157000.0 in 2021, then crashed by 2882.17% to -$4.7 million in 2022, then skyrocketed by 560.04% to $21.5 million in 2023, then tumbled by 83.39% to $3.6 million in 2024, then surged by 86.7% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Net Cash Flow are $6.7 million (Q4 2025), -$4.0 million (Q3 2025), and -$1.5 million (Q2 2025).